Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
85 results about "Hedgehog signalling" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pyridyl inhibitors of hedgehog signalling
InactiveUS20090281089A1Suppression problemBiocideGroup 5/15 element organic compoundsMalignancyMedicinal chemistry
Owner:GENENTECH INC +1
RNA interference modulators of hedgehog signaling and uses thereof
InactiveUS20050256076A1Promote growthReduce proliferationSenses disorderNervous disorderHedgehog signallingCell biology
The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.
Owner:CURIS INC +1
Pyridyl inhibitors of hedgehog signalling
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:CURIS INC +1
Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
This invention relates, e.g., to a synthetic compound, Oxy149, having the structure (Formula I) or a bioactive or pharmaceutical composition comprising Oxy149 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders. Oxy149 can be delivered either locally or systemically.
Owner:RGT UNIV OF CALIFORNIA +1
Pyridyl inhibitors of hedgehog signalling
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:GENENTECH INC +1
Modulators of hedgehog signaling pathways, compositions and uses related thereto
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. Such methods and reagents may also inhibit the hedgehog pathway in normal cells, e.g., where normal levels of hedgehog signalling are unwanted.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Modulators of hedgehog signaling pathways, compositions and uses related thereto
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors
The invention relates to pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors. The inhibitors are compounds with the structure represented by formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to a medicinal use of the above compounds as hedgehog signal conduction inhibitors.
Owner:HAINAN SIMCERE PHARMA CO LTD
Pyridyl inhibitors of hedgehog signalling
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:GUNZNER JANET L +11
Bicyclic heterocyclic amine Hedgehog signal pathway inhibitor
The invention relates to the field of biological medicine, and concretely relates to bicyclic heterocyclic amine compounds, and the compounds are a new Hedgehog inhibitor and pharmaceutically acceptable salts shown as a general formula (I). The compounds can be used as a Hedgehog signal conduction inhibitor applied to multiple medical applications.
Owner:HAINAN SIMCERE PHARMA CO LTD
Pyridyl inhibitors of hedgehog signalling
The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
Owner:CURIS INC +1
Therapeutic use
Use of an inhibitor of a Hedgehog signalling pathway, or an inhibitor of a pathway which is a target of the Hedgehog signalling pathway in the preparation of a medicament for treatment of epithelial cell hyperplasia, fibrosis of tissue, inflammation, cancer or an immune disorder.
Owner:CELLDEX THERAPEUTICS LIMITED
Rubiaceae-type cyclopeptide taken as Hedgehog signal channel inhibitor as well as preparation method and application of rubiaceae-type cyclopeptide
The invention provides a rubiaceae-type cyclopeptide taken as a novel Hedgehog signal channel inhibitor as well as a preparation method and an application of the rubiaceae-type cyclopeptide in preparation of a medicine for treating and preventing relevant cancers activated by the abnormity of Hedgehog signal channels. The rubiaceae-type cyclopeptide is prepared by the condensation of one D-alpha-alanine, one L-alpha-alanine, three substituted N-methyl-L-alpha-tyrosines and one L-alpha-amino acid of another type via peptide bonds, wherein six amino acids are condensed into an eighteen-membered rings; and benzene rings between two adjacent tyrosines are connected via an oxygen bridge so as to form a fourteen-membered ring.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
Bisamide Inhibitors of Hedgehog Signaling
The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:wherein ring A, ring B, R1, R2, R3, R4, R5, m and n are as defined herein.
Owner:GENENTECH INC +1
Composition and methods for modulating CNS activity
InactiveUS20050203014A1Function increaseModulate activityNervous disorderPeptide/protein ingredientsDiseaseNeurogenesis
The present invention concerns the methods and compositions for treating depression and other behavioral and / or emotional disorders of the central nervous system by administering an agonist of hedgehog signaling. Other disorders amenable to treatment by the subject method include attention deficit hyperactive disorders, non-Alzheimer dementia, and various symptoms of memory loss. The present invention also concerns the methods and compositions for enhancing memory and / or cognitive functions, both in a patient suffering from ailment affecting these functions, and in a subject with no diagnosed deficit in memory or cognitive function. The methods and compositions of the present invention stimulate neurogenesis and differentiation, and enhance synaptic transmission of neurons.
Owner:CURIS INC
Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
ActiveCN101993415AEffective treatmentInhibition of abnormal growth statusOrganic active ingredientsOrganic chemistryMedicineHedgehog signalling
The invention provides a compound of general formula I as an inhibitor and a preparation method thereof. The compound is used for inhibiting a Hedgehog signal path and can provide a new medicine for clinic effective cancer resistance. The invention also provides a medicine composition as an inhibitor, which contains the compound I as an effective ingredient and can be used for inhibiting the Hedgehog signal path so as to resist cancer. In addition, the invention also provides an application of the compound in the preparation of the medicine for inhibiting the Hedgehog signal path.
Owner:BEIJING HANMI PHARMA CO LTD
Hedgehog signaling promotes the formation of three dimensional cartilage matrices
InactiveUS7160725B2Reduce the impactPrice can be significantBiocidePeptide/protein ingredientsDiseaseMedicine
Owner:CURIS INC
Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
InactiveUS20100080855A1Reduce in quantityBiocideInorganic active ingredientsHematopoietic cellImatinib
The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell malignancy in a subject by administering the Hh pathway antagonist, such as the Smo antagonist cyclopamine, in combination with the ABL-kinase antagonist imatinib.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
The invention provides isoquinoline, quinoline, and quinazoline derivatives to treat a variety of disorders, diseases and pathologic conditions, and more specifically to the use of isoquinoline, quinoline, and quinazoline derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds to the treatment of hyperproliferative diseases and pathologic angiogenesis.
Owner:NANTBIOSCI
In vitro pancreatic differentiation of pluripotent mammalian cells
This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.
Owner:CAMBRIDGE ENTERPRISE LTD
Bisamide inhibitors of hedgehog signaling
Owner:GENENTECH INC +1
Targeting nucleic acid drug as well as preparation method and application thereof
ActiveCN110755382APromote enrichmentPrevent recurrenceOrganic active ingredientsMacromolecular non-active ingredientsCancer cellApoptosis
The invention provides a targeting nucleic acid drug as well as a preparation method and an application thereof. The targeting nucleic acid drug comprises an amino lipid-hyaluronic acid conjugate, a cationic liposome and a complex containing protamine, chondroitin sulfate and a nucleic acid drug, the amino lipid part of the amino lipid-hyaluronic acid conjugate is combined with the cationic liposome, and the cationic liposome wraps the complex. The targeting nucleic acid drug inhibits self-renewal and migration invasion of cancer cells by specifically blocking a Hedgehog signal transduction pathway of cell self-proliferation and differentiation, induces cell apoptosis, and can effectively inhibit recurrence of tumors.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Method for using BOC/CDO to modulate hedgehog signaling
The present invention provides for a method of using BOC / CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.
Owner:CURIS INC +1
RNA interference modulators of hedgehog signaling and uses thereof
InactiveUS8802639B2Promote growthReduce proliferationSenses disorderNervous disorderDiseaseHedgehog signalling
The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment of a number of disease conditions.
Owner:CURIS INC +1
Compounds and methods for the prevention and treatment of cancer
The present invention relates to compounds for modulating sonic hedgehog signaling and preventing or treating cancer.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1
Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders.
Owner:RGT UNIV OF CALIFORNIA
Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
Owner:NANTBIOSCI
Oxysterols and hedgehog signaling
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit Hedgehog signaling. Also described herein are methods for using such Hedgehog signaling inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of Hedgehog signaling.
Owner:MAX BIOPHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com